Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.

ABSTRACT:

Background

Modifications of FOLFIRINOX are widely used despite the absence of prospective data validating efficacy in metastatic disease (metastatic pancreatic cancer (MPC)) or locally advanced pancreatic cancer (LAPC). We conducted a multicentre phase II study of modified FOLFIRINOX in advanced pancreatic cancer to assess the impact of dose attenuation in MPC and efficacy in LAPC.

Methods

Patients with untreated MPC or LAPC received modified FOLFIRINOX (irinotecan and bolus 5-fluorouracil reduced by 25%). Adverse events (AEs) were compared with full-dose FOLFIRINOX. Response rate (RR), median progression-free survival (PFS) and median overall survival (OS) were determined.

Results

In total, 31 and 44 patients with LAPC and MPC were enrolled, respectively. In MPC, eff

SUBMITTER: Stein SM 

PROVIDER: S-EPMC4984865 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature